Kun-Yu Zhang

Real-world clinical outcomes of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) approved for HER2-low metastatic breast cancer (mBC), showing improved survival outcomes in clinical trials. However, real-world evidence on its effectiveness among Chinese patients remains limited. Patients with...